The Biomembrane Institute

Blaze Bioscience, Inc.

Seikagaku Corporation

University of Washington

Mark R Stroud

Scott R Presnell

Julia E Novak

Sen-itiroh Hakomori

Natalie Winblade Nairn

Dennis M Miller

Sen-Itiroh Hakomori

Edward D Nudelman

Steven B Levery

Claudia Jochheim

Kazuko Handa

Stacey J Hansen

Mary Ellen Salyan

Valorie R Wiss

Kelly Byrnes-Blake

Henrik Clausen

Walter E Stamm

Ann Stapleton

Mary Ellen Salvan

Khalid K Sadozai

Greg T Hermanson

Kenneth Grabstein

Peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or bind to the cartilage or kidney of a subject are disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of an active agent to a target region, tissue, structure or cell in the cartilage. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to target regions, tissues, structures, or cells targeted by the peptide.

Tissue-homing peptide conjugates and methods of use thereof

Peptide-immuno-oncology agent complexes ('peptide-I/O complexes') that can home, target, migrate to, are directed to, are retained by, accumulate in, penetrate, or bind to the tumor microenvironment, tumor tissues, or cells or compartments or cytosol of cells thereof, or any combination thereof, are disclosed. Additionally disclosed are peptide-I/O complexes that can cross the blood-brain barrier. Pharmaceutical compositions and uses for peptide-I/O complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of an immuno-oncology agent (“I/O”) to the tumor microenvironment. Targeted compositions of the disclosure can deliver peptide-I/O complexes to target regions, tissues, structures or cells targeted by the peptide.

Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof

Cartilage-homing peptide conjugates and methods of use thereof

A variety of compounds are provided which are useful as immunogens and as tumor markers. The present invention discloses methods relating to the detection of cancer. Extended forms of the lacto-series type 1 chain are shown to be present in various cancer tissues. The present invention also provides a cell line and the monoclonal antibody produced therefrom. Such an antibody has a number of uses, including in diagnostic or therapeutic methods.

Extended type 1 chain glycosphingolipids as tumor-associated antigens

An unbranched polylactosamine comprising at least 6 monosaccharides and having terminal .alpha.2.fwdarw.3 sialylation and internal .alpha.1.fwdarw.3 fucosylation at various N-acetylglucosamine residues except for solely at the penultimate N-acetylglucosamine residue.

Carbohydrate ligands (myelorollin) that cause E-selectin dependent cell

A method for determining susceptibility to E. coli urinary tract infection comprising assaying a sample of epithelial cells for the presence or absence of at least one of Le.sup.a, sialosyl galactosyl-globoside, disialosyl galactosyl-globoside and an extended globo structure carrying the same terminal epitopes as Le.sup.a, sialosyl galactosyl-globoside or disialosyl galactosyl-globoside or assaying a sample of vaginal secretions for the presence or absence of at least one of sialosyl galactosyl-globoside or disialosyl galactosyl-globoside, and detecting the presence or absence of the at least one of Le.sup.a, sialosyl galactosyl-globoside, disialosyl galactosyl-globoside and the extended globo structure, as well as a method for diagnosing secretors and nonsecretors of histo-blood group antigens comprising assaying a sample of vaginal epithelial cells, vaginal secretions or buccal epithelial cells for the presence or absence of at least one of sialosyl galactosyl-globoside and disialosyl galactosyl-globoside, and detecting the presence or absence of the at least one of sialosyl galactosyl-globoside and disialosyl galactosyl-globoside, and a method for diagnosing secretors of histo-blood group antigens comprising assaying a sample of vaginal epithelial cells or vaginal secretions for the presence or absence of at least one of globo H, globo ABO and lacto ABO, and detecting for the presence or absence of the at least one of globo H, globo ABO and lacto ABO and, further, a medicament comprising a biologically effective amount of at least one E. coli bacterial receptor analogue, and a pharmaceutically acceptable diluent, carrier or excipient as well as a method for preventing E. coli urinary tract infection comprising administering to a host a biologically effective amount of at least one E. coli bacterial receptor or bacterial receptor analogue.

Method for determining susceptibility to Escherichia coli urinary tract

A variety of compounds are provided which are usefdl as immunogens and as tumor markers. The present invention discloses methods relating to the detection of cancer. Extended forms of the lacto-series type 1 chain are shown to be present in various cancer tissues. The present invention also provides a cell line and the monoclonal antibody produced therefrom. Such an antibody has a number of uses, including in diagnostic or therapeutic methods.

The invention relates to antibodies that specifically bind a myelorollin comprising an unbranched polylactosamine comprising at least 10 monosaccharides and having terminal .alpha.2.fwdarw.3 sialylation and internal .alpha.1.fwdarw.3 fucosylation at various N-acetylglucosamine residues except the penultimate N-acetylglucosamine residue. The invention also relates to a method of using such antibodies to inhibit E-selectin-dependent rolling of a cell on another cell, wherein one of the cells expresses a myelorollin that binds the antibodies.

Antibodies that bind novel carbohydrate ligands (myelorollins) that

A process for preparing difucosyl Y.sub.2 antigen (dimeric Le.sup.x) , said process comprising: (1) preparing a lactonorhexaosylceramide backbone or a lactonorhexaosylsaccharide backbone linked to a carrier molecule; and (2) enzymatically fucosylating said backbone at the III.sup.3 and V.sup.3 positions through an .alpha.1.fwdarw.3 linkage. A process for preparing Le.sup.y antigen analogues, said process comprising: (1) preparing a lactonorhexaosyl-ceramide backbone or a lactonorhexaosylsaccharide backbone linked to a carrier molecule; and (2) enzymatically fucosylating said backbone at the terminal .beta.-Gal through an .alpha.1.fwdarw.2 linkage; and (3) enzymatically fucosylating said backbone at one or more positions through an .alpha.1.fwdarw.3 linkage, provided that steps (2) and (3) can be conducted simultaneously or in any order. A process for preparing a fucosylated lactonorhexaosylceramide, lactonorhexaosylsaccharide linked to a carrier molecule or higher analogues thereof, said process comprising: (1) preparing a lactonorhexaosylceramide backbone, a lactonorhexaosylsaccharide backbone linked to a carrier molecule or backbones of higher analogues thereof; and (2) enzymatically fucosylating one or more residues of said backbone. A process for preparing sialyl Le.sup.x and sialyl dimeric Le.sup.x.

Synthesis of Le.sup.x ; dimeric Le.sup.x (difucosyl Y.sub.2 ; III.sup.3

A substantially pure unbranched ceramide polysaccharide type 2 chain compound having the following structure: ##STR1## wherein Gal represents galactose, GlcNAc represents N-acetylglucosamine, Fuc represents fucose Glc represents glucose and Cer represents ceramide. A substantially pure unbranched ceramide polysaccharide type 2 chain compound having the following structure: ##STR2## wherein Gal represents galatose, GlcNAc represents N-acetylglucosamine. Fuc represents fucose, Glc represents glucose, Cer represents ceramide and NeuAc represents sialic acid. Antibodies that are specific to portions of the above-described compounds, wherein the portions comprise the internal .alpha.1-.fwdarw.3 fucosyl residue and/or the terminal sialic acid residue. Immuogens for producing antibodies to the above-described compounds or portions thereof. A method of actively immunizing against tumors that express the above-described compounds.

Growing community of inventors

Seattle, WA, United States of America

Mark R Stroud